The Indian Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned “Roche, Glenmark Settle Patent suit over cancer drug”.
As a response, the company on Tuesday said it has vide email dated January 04, 2016 has submitted that Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine – Erlotinib Hydrochloride.
“As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company,” it has been revealed in the company’s press release.